Aimspro – Stop Press

Dramatic Improvement’ in Eyesight Problems with Aimspro

The results of the optic neuritis trial in Oxford are very good. Patients’ vision improved significantly following treatment with Aimspro.

The MS patients who took part in the double blind trial at the John Radcliffe Hospital showed improvement in visual field scores over a two week course of treatment. These highly significant improvements in the patients’ sight were observed after only three injections, so the possibility of a placebo effect was excluded. There were no side effects.

This is the first time that any treatment has been shown conclusively to reduce an aspect of disability in the chronic phases of MS to this degree.

Dr Bryan Youl, a consultant in Clinical Neurophysiology at the Royal Free Hospital in London, whose own findings on Aimspro in MS and other neurological conditions are about to be published, said: “These trial results are hugely significant and have wider implications for the treatment of MS. Although this was a small trial, the Oxford neurologists have shown that a brief course of three well tolerated sub-cutaneous injections of Aimspro can demonstrably improve the condition of MS patients. They echo other clinical observations which show this drug is able to improve mobility, bladder control and energy levels among MS patients.”

The Oxford trial confirms Dr Youl’s own findings in observational studies carried out last year in London. He said: “Within one hour of injection there was a significant improvement in colour vision, and comparison of pre-treatment and follow-up data also showed significant benefit.”

He added: “Aimspro has a powerful and often rapid effect, producing dramatic improvement. We believe it to be restoring conduction in nerve and muscle fibres damaged by MS and other central and peripheral nervous system disorders, probably by an effect on biological structures within nerve and muscle known as voltage gated sodium channels. There is also clinical evidence to suggest that there may also be a repair process taking place in the longer term, which may reflect the medication’s powerful anti-inflammatory properties.”

Oxford University’s Professor of Neurology, Paul Matthews, who led the trial, said: “The results of this trial in terms ofAimspro’s effect on visual impairment are encouraging. We studied vision because it can guide expectations for other functional impairments caused by MS. By studying the effects of a drug on vision in patients with optic neuritis we can reasonably expect to understand possible effects of the drug on the disease as it affects other parts of the brain. As far as we know, the factors that are responsible for impairment of vision in multiple sclerosis associated with optic neuritis are the same as those that impair other systems in the brain.

“Using Aimspro we found that in a tertiary outcome measure there was a significant treatment effect on visual fields and the drug was well tolerated. It is encouraging that a possible effect of Aimspro occurred relatively rapidly. If this is a true result, it would be consistent with the fact that Aimspro has an immunological mechanism. This needs to be investigated further.”

The Aimspro trial at the John Radcliffe was a randomised, double blind, placebo controlled, crossover trial, independently designed and analysed by two of Britain’s leading MS experts, Prof. Paul Matthews and Dr. Jackie Palace, and their research fellow Dr. Georgina Burke. Patients and researchers were ‘blinded’ as to whether participants were receiving Aimspro or placebo. The crossover design meant that each patient received two weeks (three injections) of medication, and two weeks of placebo.

This site is hosted by names.co.uk and the domain name has been registered with them. I have found them to be reasonably priced, helpful and reliable. So, if you are looking for domain name registration or web site hosting, click the above banner.